Cellosaurus NCI-H1975 (CVCL_1511)

Cell line name NCI-H1975
Synonyms H1975; H-1975
Accession CVCL_1511
Resource Identification Initiative To cite this cell line use: NCI-H1975 (RRID:CVCL_1511)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
Part of: MD Anderson Cell Lines Project.
Doubling time: 38.7 +- 5.92 hours (PubMed=25008024); 28 hours (PubMed=25984343).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: EGFR p.Leu858Arg and p.Thr790Met (PubMed=17332333).
Omics: Deep exome analysis.
Omics: Deep membrane proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_DG25 (H1975/WR); CVCL_LC85 (NCI-H1975 KRAS (G12D/+)); CVCL_4W96 (NCI-H1975-Luc); CVCL_HF59 (NCI-H1975/GR)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12
D13S31710,13 (AddexBio; ATCC; Cosmic-CLP)
10 (PubMed=25877200)
D16S5399,12
D18S5113
D21S1128
D3S135814,15
D5S81811,12
D7S8208,11 (AddexBio; ATCC)
8 (Cosmic-CLP; PubMed=25877200)
D8S117913,16
FGA21,24
Penta D12,13
Penta E12,16
TH017
TPOX8,11
vWA18
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339
Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Cancer Res. 67:2046-2053(2007)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

PubMed=21498706
Onitsuka T., Uramoto H., Tanaka F.
Lack of direct association between EGFR mutations and ER beta expression in lung cancer.
Anticancer Res. 31:855-860(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25008024; DOI=10.1007/s10735-014-9583-2
Wang J., Wei H., Zhao B.-X., Li M., Lv W.-P., Lv L., Song B., Lv S.
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
J. Mol. Histol. 45:641-652(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477
Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
J. Proteome Res. 14:3658-3669(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639
Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Anal. Chem. 87:12016-12023(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections AddexBio; C0016013/4946
ATCC; CRL-5908
BCRJ; 0352
ICLC; HTL06001
KCB; KCB 2014034YJ
Cell line databases/resources CLDB; cl7204
CCLE; NCIH1975_LUNG
CCRID; 3111C0001CCC000252
Cosmic-CLP; 924244
GDSC; 924244
IGRhCellID; NCIH1975
LINCS_LDP; LCL-1663
Ontologies BTO; BTO:0004824
CLO; CLO_0008035
EFO; EFO_0002271
Biological sample resources BioSample; SAMN03471753
BioSample; SAMN03472594
Chemistry resources ChEMBL-Cells; CHEMBL3307601
ChEMBL-Targets; CHEMBL614348
Gene expression databases GEO; GSM206481
GEO; GSM253304
GEO; GSM434293
GEO; GSM513951
GEO; GSM514336
GEO; GSM782116
GEO; GSM794340
GEO; GSM887393
GEO; GSM888471
GEO; GSM1374716
GEO; GSM1670203
Polymorphism and mutation databases Cosmic; 687808
Cosmic; 903607
Cosmic; 924244
Cosmic; 930487
Cosmic; 1028949
Cosmic; 1047098
Cosmic; 1128244
Cosmic; 1146894
Cosmic; 1154595
Cosmic; 1336879
Cosmic; 1513408
Cosmic; 1571739
Cosmic; 1609518
Cosmic; 1741781
Cosmic; 1795297
Cosmic; 1802294
Cosmic; 1995548
Cosmic; 2042865
Cosmic; 2125194
Proteomic databases PRIDE; PXD001548
PRIDE; PXD002224